Glaxo SmithKline K.K. has announced it will import 2 million doses of the antiflu drug Relenza from France by April, as an emergency measure to cope with the spread of flu viruses resistant to Tamiflu, the drug most commonly prescribed for flu.
According to the National Institute of Infectious Diseases, about 52 percent of flu viruses detected this winter have been of the influenza A virus subtype H1N1, with most of them proving resistant to treatment with Tamiflu.
As a result, the number of medical institutions prescribing Relenza instead of Tamiflu has increased rapidly.
According to Glaxo SmithKline, the company will import 400,000 doses of Relenza this month, 600,000 doses in March, and 1 million doses in April.
No comments:
Post a Comment